The inflammatory response to acute or chronic tissue injury engages the immune system. What are the initial activators of injury or disease? How does the immune system discriminate between live versus dead cells and know whether to respond? What factors regulate the inflammatory response to clear injury without causing excessive tissue damage and then initiate repair? We now recognize that the well-known activation of the immune system in response to foreign pathogens is recapitulated in an immune response to endogenous molecules released from necrotic, and perhaps apoptotic, cells after tissue injury or trauma related to hypoxia, ischemia, mechanical stress, or pathogen-induced inflammation.
Matzinger 1 originally proposed the danger model to clarify exceptions to Janeway's model 2 of the immune response to foreign antigens, which did not at the time explain autoimmunity or the immune response to transplantation. The danger model suggests that damaged or dying cells release endogenous molecules called damage/danger-associated molecular patterns (DAMPs) that activate the immune system in a fashion analogous to pathogen-associated molecular patterns (PAMPs), molecules released by pathogenic bacteria or viruses. These endogenous or self-molecules (extracellular matrix proteins (ECM), calciumbinding proteins, and structural proteins) typically function in normal cell homeostasis but are also recognized as danger signals when released into the extracellular space 3 exposing hydrophobic portions of the molecules that are normally hidden in healthy living cells. 4 Matzinger 4 -6 and others have extended the danger model as more has been learned about the role of danger signals in tissue injury 7, 8 and diseases such as arthritis 9 and cancer 10,11 and the body's need for mechanisms that dampen the immune response and initiate repair. Here we focus on the role of DAMPs and ligands of Toll receptors (TLRs) in renal disease [12] [13] [14] [15] and expand recent interest to a broader view of the currently identified classes of DAMPs and their putative receptors.
DANGER-ASSOCIATED MOLECULAR PATTERNS: ENDOGENOUS DANGER SIGNALS
A consistent terminology has not been adopted for the endogenous molecules that convey a danger signal to the immune system. Some DAMPs that stimulate an immune response have been called adjuvant molecules to distinguish them from DAMPs that produce only acute pro-inflammatory effects, 3 sometimes referred to as alarmins. 16, 17 PAMPs and alarmins have been grouped together as subcategories of a large family of DAMPs, 16,17 whereas others consider alarmins and DAMPs to be related molecules that are clearly distinguished from PAMPs. 9 Here we use the term DAMPS to describe endogenous danger mole-cules as a group that is separate from pathogen-derived PAMPs (Table 1 and Figure 1 ); their classification is predicated on direct evidence of involvement in the immune response to injury with a clear absence of confounding effects from potential bacterial contaminants, such as LPS. 3, 16 High-mobility Group Box 1 Protein
Perhaps the most well characterized DAMP, high-mobility group box 1 (HMGB1) protein, is a ubiquitously expressed nonhistone DNA-binding protein that regulates chromosomal stability, stabilizes nucleosomes, and regulates transcription. 18 -22 As an extracellular DAMP after secretion or passive release, 23 HMGB1 is a late-phase pro-inflammatory mediator in sepsis 24 and in sterile inflammation, such as hepatic ischemia-reperfusion injury (IRI). 18, 25 HMGB1 is chemotactic for immune cells and stimulates dendritic cell (DC) maturation and migration. 26 HMGB1 binds to the receptor for advanced glycation end products (RAGE) 27 and stimulates NFB-induced transcription through interactions with TLR2, TLR4, 28 and RAGE.
S100 Protein Family
The S100 proteins, a large family of calcium-binding proteins, are implicated in the inflammation or fibrosis associated with cancer or diseases of the kidney, heart, joints, and lungs. 29 When functioning extracellularly as DAMPs after release from phagocytes 30 and other cells in response to cell stress, S100 proteins bind to RAGE 31 and other receptors and produce earlier pro-inflammatory effects like HMGB1. 32,33 S100A8 and S100A9 release from activated phagocytes activates TLR4 and amplifies lethal endotoxin-induced shock. 33 
Heat-shock Proteins
In normal healthy cells, heat-shock proteins (HSPs) are intracellular protein chaperones that guide newly synthesized polypeptide chains to prevent aggregation and misfolding. During cell stress, induction and secretion of HSPs causes pro-inflammatory cytokine and chemokine release and activation and maturation of antigen-presenting cells (APCs) to produce a robust innate immune response. 34 -36 Indeed, HSPs extend their role as chaperones intracellularly by binding and presenting antigens to cell surface MHC class I molecules. 37, 38 Complexes of extracellular HSPs and antigens are taken up by APCs and presented to MHC I to activate T cells through cross-presentation. 36, 37 Other Ligands of RAGE A diverse group of ligands (including HMGB1, S100 proteins, and HPSs) bind to RAGE. Advanced glycation end products (AGE) and related molecules are glycation and oxidation products of proteins and lipids that are formed in hyperglycemic states by oxidative stress, such as hypoxia and ischemia/reperfusion, and in a number of diseases. 39 -42 Genomic Double-stranded DNA Microbial DNA is a ligand for TLR9, but TLR9 can also recognize self-DNA from injured mammalian cells. 43 Release of DNA from dying mammalian cells initiates an innate immune response by activation of TLR9 and the NALP3 (cryopyrin) inflammasome, release of activated IL-1␤ and IL-18, 44 and induction of DC maturation. 45 In addition to genomic DNA, injury-induced release of mitochondrial DNA can also cause inflammation by conserved pathogenic PAMP sequences. 46, 47 Uric Acid
The accumulation of uric acid in tissues has long been known to cause gout, but soluble uric acid released by injured cells also acts as a danger signal. 48 The active moiety, monosodium urate crystals, forms in the extracellular space where it stimulates an immune response by activating the NALP3 inflammasome 49 -51 Other DAMPs
Other candidate DAMPs include galectins 58, 59 ; ATP and adenosine 60 -64 ; thioredoxin, a ubiquitous antioxidant enzyme 65, 66 ; the intranuclear cytokine, IL-33 67 ; and Tamm-Horsfall protein (THP; or uromodulin), a glycoprotein expressed in the thick ascending limb that is excreted into the urine after proteolytic cleavage. THP is the most abundant protein in urine, but its function remains unclear 68 ; it has been implicated as a biomarker of kidney disease and allograft rejection 69, 70 and may be a damage signal in renal tubular injury. THP promotes cytokine release 71 and immune cell activation, including DC maturation, 72 but may also have a protective anti-inflammatory role. 73 
RECEPTORS
DAMPs are recognized by pattern-recognition receptors such as certain TLRs, NOD-like receptors (NLRs, including the NLRP inflammasomes), and RLRs (RIG-I-like receptors), thereby overlapping with PAMPs, 74, 75 and by specialized receptors such as RAGE. 76 Common signaling pathways shared by DAMPs and PAMPs may have an evolutionary basis. 47 Injury-induced release of bacterial-related DAMPs from mitochondria, evolutionary symbiotic descendents of bacteria, causes inflammation. 46 Other DAMPs receptors include CD91, scavenger receptors, CD2, integrins, chemokine receptors, and CD44. 3, 11, 16, 74 RAGE is a multiligand receptor that binds AGE, some S100 proteins, amyloid protein, and HMGB1. It amplifies immune responses 39 and is implicated in diseases such as diabetes, Alzheimer's disease, cancer, and various inflammatory conditions. 40, 76, 77 A soluble form of RAGE (sRAGE) found in human and mouse plasma 78 may act as a ligand decoy to bind danger molecules and check the immune response. Circulating sRAGE and a splice variant (endogenous secretory RAGE) may be clinical indicators or biomarkers for the severity of disease. 41, 79 Inflammasomes, large cytosolic complexes of NOD-like receptors, adaptor protein, and caspase-1, link pathogenic and endogenous danger signals to activation of caspase-1, and proteolytic processing and release of the proinflammatory cytokines, IL-1␤, and IL-18. 50, 80, 81 Inflammasomes are important in gout, 82 and their role in disease has been linked to several DAMPs, including the ECM molecule, biglycan. 57 
CHECKS AND BALANCES
With such a vast array of stranger and danger signals and some crossover in 84, 85 and selective suppression of DAMP signaling (Figure 2 ). [85] [86] [87] Some mechanisms control damageinducing immune responses through DAMPs inactivation. Anti-HMGB1 antibodies 88 and sRAGE reduce HMGB1 bioavailability. 40 Extracellular redox conditions may regulate the immune response by balancing early-stage reducing environment-promoting pro-inflammatory conditions with late-stage oxidation-induced DAMPs inactivation; disruption of this balance may contribute to chronic inflammation. 19,89,90 BCL2 proteins, a family of pro-or antiapoptotic moieties, may be tissue protective when released extracellularly in IRI. 91 Some endogenous molecules contribute to the resolution of inflammation and initiation of renal repair. 92 WeibelPalade bodies are organelles of endothelial cells that contain bioactive substances such as von Willebrand factor, IL-8, P-selectin, angiopoietin-2, and eotaxin 93 that participate in hemostasis and inflammation. Uric acid release after IR mobilizes stem cells, protects kidneys from injury, 94, 95 and through exocytosis of Weibel-Palade bodies and release of their constituent molecules may promote postischemic repair. 96 Some DAMPs, including HMGB1 and some ECM proteins, such as hyaluronan and heparin sulfate, initiate immune responses but are also necessary for recovery and healing. 19 
DAMPS AND KIDNEY DISEASE
Despite significant advances in understanding the important contribution of inflammation and immune mechanisms to the pathogenesis of a variety of kidney diseases, few specific or efficacious therapies exist. Understanding the role of candidate DAMPs released from somatic kidney or immune cells could reveal novel drug targets for inhibiting the inflammatory response or promoting repair processes in acute and chronic kidney disease (CKD). DAMPs contribute to multiple diseases. TLRs are important in IRI and various forms of glomerulonephritis including lupus nephritis. 12-15 Advanced glycation end products, DAMPs that bind to RAGE rather than TLRs, are increased in renal failure and are involved in the progression of CKD in diabetic and nondiabetic kidney disease. 97, 98 Acute Kidney Injury Acute kidney injury (AKI) results most commonly from IR, and although there are many causes, a common pathway leading to proximal tubule injury is activation of innate and adaptive immunity leading to inflammation. 99 Injury elicits release of pro-inflammatory DAMPs, 107 High concentrations of uric acid accumulate in ischemic tissues and precipitate to form monosodium urate crystals that elicit an immune response. However, a single treatment with uric acid or the enzyme uricase to produce an acute rise in blood levels of uric acid mobilized endothelial progenitor cells and protected kidneys from IRI; this effect was absent with hyperuricemia. 95 Kidney injury molecule-1 (Kim-1/ Tim-1), one of a growing list of biomarkers of AKI and CKD, is a multifunction receptor protein expressed in proximal tubules that is released into the urine of patients with kidney disease. 108 In addition to imparting phagocytic properties to tubule epithelial cells, 109 Kim-1/ Tim-1 may inhibit development of autoimmune responses and promote resolution of inflammation after kidney injury, 108 therefore suggesting its role as a possible DAMP molecule or receptor.
Diabetic Nephropathy and Nondiabetic Glomerular Diseases
There is expansive literature on the involvement of AGE and RAGE in podocytes, diabetes, and diabetic nephropathy. 42,76,97,110 -117 It is presumed but not always demonstrated that these molecules are important as DAMPs because of the involvement of inflammation and the immune system in diabetes. 42,115,118 -120 RAGE, functioning as an endothelial adhesion receptor, is implicated in a novel pathway for leukocyte recruitment in inflammatory disorders and diabetic mice, and this process is enhanced by S100, a proinflammatory RAGE ligand. 121 Experiments using RAGE null or overexpressing mice, neutralizing RAGE antibodies, or sRAGE implicate RAGE in the pathophysiology of diabetic nephropathy and chronic inflammation. 76, 112, 122 In db/db mice, increased RAGE and S100 expression in podocytes associates both with renal pathology and with increased infiltration of mononuclear phagocytes to glomeruli; these effects are blocked by anti-RAGE antibody. 112 Serum RAGE levels, kidney damage, and inflammatory mediators in diabetic animals and humans are inversely related to levels of AGE receptor-1, 123, 124 suggesting an anti-inflammatory protective role for AGE receptor-1 in diabetes. 123 AGE, RAGE, 97, 117 and other DAMPs are also strongly implicated in the pathogenesis of nondiabetic glomerular diseases. Podocyte injury and adriamycin-induced glomerulosclerosis are accompanied by production of RAGE ligands; RAGE-deficient or sRAGE-treated mice are protected from glomerular injury. 125 Increased AGE and RAGE levels, macrophage infiltration, fibrosis, and inflammation are found in the kidneys of mice that develop glomerular disease from an atherogenic high-fat diet; this lipid-induced renal injury is regulated in part by galectin-3. 126 TLR4 is up-regulated in mouse models of cryoglobulinemic membranoproliferative glomerulonephritis and localizes to podocytes of nephritic glomeruli; stimulation of podocytes with either TLR4 ligands or fibrinogen results in similar patterns of enhanced chemokine expression, suggesting that TLR4 functions as a DAMPs receptor for endogenous ligands and may mediate glomerular injury by stimulating innate immunity. 127 In nephrotoxic nephritis, a model of rapidly progressive glomerulonephritis, Hsp60 is released from kidneys and excreted in urine, and administration of Hsp60 exacerbates disease in a T cell-dependent manner. 128 Expression of S100 proteins increases in kidneys in anti-Thy-1 antibody-induced glomerulonephritis, a rat model of mesangial proliferative glomerulonephritis. 129 Patients with glomerulonephritis have HMGB1 in serum, interstitial mononuclear cells, and glomeruli. 130 Two S100 proteins, myeloid-related proteins MRP8 and MRP14, are detected in macrophages in renal biopsies from patients with glomerulonephritis; the presence of these proteins and their heterodimeric complexes in macrophages infiltrating glomeruli correlates with the severity of the acute inflammatory process, and chronic inflammation associates with MRP8/MRP14 infiltrates without complex formation in the renal interstitium. 131 
Fibrosis
Expression of Hsp27, phospho-Hsp27, 132 RAGE, 133 and calreticulin 134 is up-regulated in an animal model of tubulointerstitial fibrosis (unilateral ureteral obstruction [UUO]) and TGF␤-induced epithelial-to-mesenchymal transition in proximal tubular epithelial cells in vitro. The ECM protein, biglycan, increases in tubule epithelial cells 4 days after UUO and later in infiltrating and interstitial cells. 135 Biglycan is a pro-inflammatory DAMP in UUO-induced kidney injury; activation of the NLRP3 inflammasome and increases in levels of pro-inflammatory IL-1␤ after UUO are reduced in biglycan null mice. 57 Reactive oxygen species, oxidative stress, S100A4, and Hsp47 are involved in fibrosis after IRI, but their role in immune function has not been investigated. 136 Lupus Nephropathy and Autoimmune Disease HMGB1 has been linked to the pathogenesis of a variety of proinflammatory and autoimmune diseases, including systemic lupus erythematosus (SLE). 137 Circulating HMGB1 levels increase in SLE patients and in mice, 138, 139 and HMGB1 may be involved in antibody-induced kidney damage in SLE. 140 In lupus-prone MRL-Fas(lpr) mice, p38 MAPK activation-induced infiltration and maturation of DCs and secretion of HMGB1 from DCs have been implicated in autoimmune kidney disease. 141 Inflammatory and immune responses in SLE, and particularly in lupus nephritis, can be induced by HMGB1-nucleosome complexes, 138, 142 but necrotic nucleosomes also contain double-stranded DNA, which has long been recognized as a key mediator of lupus nephritis. Chromatin fragments can participate in the pathogenesis of kidney disease in SLE by stimulating the innate immune system and by engaging the adaptive immune response to produce antichromatin and anti-double-stranded DNA antibodies leading to glomerular deposits of immune complexes, which are the hallmark and likely the critical initiating events in lupus nephritis. 143 
Transplantation
The contribution of DAMPs to IRI is likely also pertinent in kidney transplantation, because donor kidneys are susceptible to delayed graft function resulting from ischemia followed by reperfusion. Release of DAMPs, such as HMGB1, ATP, uric acid, and IL-1␣, from allografts may induce pro-inflammatory effects and adaptive immune responses. 144 TLRs mediate the effects of some these endogenous molecules in transplant by signaling through type 1 interferons. 145 In human kidney transplants, increased expression of TLR4 and HMGB1 is found in deceased donor kidneys, and kidneys from patients with a TLR4 loss-of-function mutation have lower levels of inflammatory markers and improved graft function post-transplant. 146 Moreover, TLRs and their endogenous ligands may be important in chronic allograft dysfunction. Expression of DAMPs, including biglycan, HSPs, fibrinogen, and HMGB1, increases in the acute and chronic phases after kidney transplantation. 147 Kidney transplants to mice lacking TLR2, TLR4, or the adaptor proteins, MyD88 and TRIF, show improved graft function and morphology and decreased leukocyte infiltration and expression of fibrotic markers, cytokines, and chemokines. 147 Higher levels of S100A8 and S100A9 in renal biopsies taken in the acute phase after transplant are predictive of favorable graft outcome (patients that later had stable graft function compared with those progressing to chronic allograft nephropathy) 148 ; these S100 proteins are typically pro-inflammatory, but their beneficial role in wound repair may predominate in transplantation and rejection. Glycosylation of Tamm-Horsfall glycoprotein is altered, and its various immunomodulatory functions are diminished in renal transplant patients at least in part because of altered NF-B p52 nuclear translocation. 149 
Nondiabetic Chronic Kidney Disease
Many of the DAMPs molecules associated with AKI are also important in CKD. Increased HMGB1 levels correlate with pro-inflammatory markers and declining kidney function in CKD. 150 Endothelial dysfunction in CKD, which associates with elevated serum levels of AGE, may be due to AGE-induced suppression of endothelial NOS. 151 RAGE is proinflammatory in hemodialysis patients 152 ; sRAGE and endogenous secretory RAGE levels inversely correlate with renal function and inflammatory state in hemodialysis patients. 153, 154 Elevated TLR2 expression in patients with CKD and in mice with obstructive nephropathy associates with inflammation and increased expression of biglycan and HMGB1, but TLR2 may not be necessary for chronic kidney injury. 155 By contrast Tamm-Horsfall protein activates innate and adaptive immunity through TLR4 72 and may play an inflammatory role in progression of CKD. 71 Levels of HSPs, anti-HSP antibodies, and inflammatory markers are higher in children and young adults with CKD. 156 
CONCLUSIONS
Processes that contribute to the pathogenesis of acute and chronic kidney disease involve the activation of innate and adaptive immunity. Release of endogenous molecules from dying cells leads to activation of innate immunity and downstream inflammation. By bridging to adaptive immunity, DAMPs also contribute to progressive injury or to attenuation of injury. As our understanding of these molecules and pathways evolves, information on precise therapeutic targets will likely lead to improved outcomes.
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